LON:INDV Indivior (INDV) Share Forecast, Price & News GBX 1,626 -36.00 (-2.17%) (As of 04:45 PM ET) Add Compare Share Share Today's Range 1,621▼ 1,68150-Day Range 1,662▼ 1,88552-Week Range 1,330▼ 2,020Volume228,021 shsAverage Volume391,503 shsMarket Capitalization£2.24 billionP/E RatioN/ADividend YieldN/APrice TargetGBX 2,460 ProfileProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines About Indivior (LON:INDV) StockIndivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesOctober 2, 2023 | finance.yahoo.comIndivior PLC (INDV): Unveiling Its Market ValueSeptember 26, 2023 | finance.yahoo.comIndivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in CanadaOctober 4, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 7, 2023 | finance.yahoo.comIndivior PLC (INDV)'s True Worth: A Complete Analysis of Its Market ValueJune 12, 2023 | finance.yahoo.comThe 7.5% return this week takes Indivior's (LON:INDV) shareholders three-year gains to 372%June 12, 2023 | finance.yahoo.comIndivior to Commence Trading on NasdaqJune 7, 2023 | msn.comJefferies Reiterates Indivior (LSE:INDV) Buy RecommendationJune 5, 2023 | reuters.comIndivior opioid settlement makes purer M&A caseOctober 4, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.June 3, 2023 | msn.comUS drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claimsJune 2, 2023 | finanznachrichten.deIndivior PLC: Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation ClaimsMay 25, 2023 | uk.finance.yahoo.comINDV.L - Indivior PLCMay 25, 2023 | finance.yahoo.comIndivior To Participate In Upcoming Investor ConferencesMay 23, 2023 | finance.yahoo.comIndivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12thMay 22, 2023 | markets.businessinsider.comFDA Approves Opiant's Nasal Spray 'Opvee' To Reverse Opioid OverdoseMay 22, 2023 | reuters.comUS FDA approves Opiant's spray for reversing opioid-related overdosesMay 22, 2023 | finance.yahoo.comIndivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like FentanylApril 27, 2023 | finance.yahoo.comIndivior Announces Q1 2023 Financial ResultsApril 25, 2023 | finance.yahoo.comIndivior To Participate In Bank of America Global Healthcare Conference 2023March 2, 2023 | finance.yahoo.comIndivior Completes Acquisition of Opiant Pharmaceuticals, Inc.February 16, 2023 | finance.yahoo.comFY 2022 Financial Results AnnouncedFebruary 6, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCJanuary 2, 2023 | finance.yahoo.comInvesting in Indivior (LON:INDV) three years ago would have delivered you a 861% gainDecember 9, 2022 | finance.yahoo.comShould You Be Excited About Indivior PLC's (LON:INDV) 73% Return On Equity?December 7, 2022 | finance.yahoo.comIndivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth OutlookNovember 14, 2022 | finance.yahoo.comIndivior To Acquire Opiant PharmaceuticalsNovember 8, 2022 | finance.yahoo.comIndivior Third Quarter 2022 Earnings: EPS: US$0.29 (vs US$0.18 in 3Q 2021)See More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:INDV CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,000Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 2,460 High Stock Price ForecastGBX 2,700 Low Stock Price ForecastGBX 2,330 Forecasted Upside/Downside+48.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.33) Trailing P/E RatioN/A Forward P/E Ratio1,567.92 P/E Growth-5.57Net Income£-59,000,000.00 Net Margins-5.89% Pretax MarginN/A Return on Equity-34.01% Return on Assets8.62% Debt Debt-to-Equity Ratio240.17 Current Ratio1.13 Quick Ratio1.52 Sales & Book Value Annual Sales£1 billion Price / Sales2.29 Cash FlowGBX 620.13 per share Price / Cash Flow2.68 Book ValueGBX 85 per share Price / Book19.55Miscellaneous Outstanding Shares137,940,000Free FloatN/AMarket Cap£2.29 billion OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Exec. DirectorMr. Ryan PreblickCFO & Exec. DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVP of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 51)Chief Legal Officer Mr. Jon FogleChief HR OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMs. Nina DeLorenzoChief Global Impact OfficerMore ExecutivesKey CompetitorsHUTCHMEDLON:HCMHikma PharmaceuticalsLON:HIKUDG HealthcareLON:UDGAbcamLON:ABCOxford Nanopore TechnologiesLON:ONTView All CompetitorsInsidersMark StejbachBought 1,400 shares on 3/6/2023Total: £2.10 M ($1,502.00/share)View All Insider Transactions INDV Stock - Frequently Asked Questions Should I buy or sell Indivior stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INDV shares. View INDV analyst ratings or view top-rated stocks. What is Indivior's stock price forecast for 2023? 2 Wall Street analysts have issued twelve-month price targets for Indivior's shares. Their INDV share price forecasts range from GBX 2,330 to GBX 2,700. On average, they predict the company's stock price to reach GBX 2,460 in the next year. This suggests a possible upside of 48.0% from the stock's current price. View analysts price targets for INDV or view top-rated stocks among Wall Street analysts. How have INDV shares performed in 2023? Indivior's stock was trading at GBX 1,852 at the start of the year. Since then, INDV shares have decreased by 10.3% and is now trading at GBX 1,662. View the best growth stocks for 2023 here. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF). What is Indivior's stock symbol? Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV." How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Indivior's stock price today? One share of INDV stock can currently be purchased for approximately GBX 1,662. How much money does Indivior make? Indivior (LON:INDV) has a market capitalization of £2.29 billion and generates £1 billion in revenue each year. The specialty pharmaceutical company earns £-59,000,000.00 in net income (profit) each year or GBX (0.33) on an earnings per share basis. How many employees does Indivior have? The company employs 1,000 workers across the globe. How can I contact Indivior? Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The official website for the company is indivior.com. The specialty pharmaceutical company can be reached via phone at +44-1753-217800. This page (LON:INDV) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.